The Journal of arthroplasty · 2026
Expert Perspectives on Disruptive Bleeding and Hemostasis Optimization in Primary and Revision Total Hip Arthroplasty: A Structured Expert-Opinion Survey.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mont Michael A, Chen Antonia F, Smitterberg Chase W, Aflatooni Justin O, Cohen-Rosenblum Anna R, Della Valle Craig J, Duensing Ian M, Edelstein Alexander I, Grynovicki Erica N, Ihekweazu Ugo N, Jenkins Scott, Jones Robert B, Marino Dominic V, Palmer Christopher W, Sierra Rafael J, Varacallo Matthew A, Zlotnicki Jason P
Аннотация
BACKGROUND: Despite advances in perioperative blood management, disruptive bleeding after total hip arthroplasty (THA) remains clinically important, given associations with hematoma, wound complications, infection, reoperation, and resource utilization. The term "disruptive bleeding" has emerged from recent outcomes and health-economic work to describe bleeding-related events that alter care, but has not been standardized as a clinical entity in THA. This survey explored whether this construct aligns with arthroplasty surgeons' perspectives and identified domains for future validation.
METHODS: A structured expert-opinion survey was distributed to 14 arthroplasty surgeons experienced in primary and revision THA. Domains included definitions of disruptive bleeding, risk factors, intraoperative diffuse oozing, postoperative drainage, escalation triggers, and topical hemostatic agent use. Responses included categorical selections, Likert-style ratings, and free-text comments. Descriptive statistics and exact denominators were reported. An agreement of at least 70% was used descriptively to identify high-agreement items.
RESULTS: All respondents supported characterizing disruptive bleeding as a composite of care-altering events, including symptomatic or management-changing hemoglobin decline greater than three g/dL, transfusion, prolonged drainage, return to the operating room, embolization, and readmission. The most frequently identified bleeding risk factors were thrombocytopenia and anticoagulant use (n = 14 of 14), followed by coagulopathy and liver disease (n = 12 of 14). Escalation triggers included suspected arterial bleeding (n = 14 of 14), enlarging hematoma (n = 13 of 14), hemodynamic instability (n = 13 of 14), neurovascular compromise (n = 13 of 14), and persistent drainage (n = 12 of 14). Only four of 14 supported routine topical hemostatic agent use in primary THA, whereas seven of 14 supported selective consideration in revision THA. Disagreement remained regarding timing definitions and drainage thresholds.
CONCLUSIONS: Disruptive bleeding in THA was viewed as a composite construct defined by care-altering events rather than numeric blood-loss measures. These findings are exploratory, hypothesis-generating, and identify candidate domains for future multidisciplinary and prospective validation.
METHODS: A structured expert-opinion survey was distributed to 14 arthroplasty surgeons experienced in primary and revision THA. Domains included definitions of disruptive bleeding, risk factors, intraoperative diffuse oozing, postoperative drainage, escalation triggers, and topical hemostatic agent use. Responses included categorical selections, Likert-style ratings, and free-text comments. Descriptive statistics and exact denominators were reported. An agreement of at least 70% was used descriptively to identify high-agreement items.
RESULTS: All respondents supported characterizing disruptive bleeding as a composite of care-altering events, including symptomatic or management-changing hemoglobin decline greater than three g/dL, transfusion, prolonged drainage, return to the operating room, embolization, and readmission. The most frequently identified bleeding risk factors were thrombocytopenia and anticoagulant use (n = 14 of 14), followed by coagulopathy and liver disease (n = 12 of 14). Escalation triggers included suspected arterial bleeding (n = 14 of 14), enlarging hematoma (n = 13 of 14), hemodynamic instability (n = 13 of 14), neurovascular compromise (n = 13 of 14), and persistent drainage (n = 12 of 14). Only four of 14 supported routine topical hemostatic agent use in primary THA, whereas seven of 14 supported selective consideration in revision THA. Disagreement remained regarding timing definitions and drainage thresholds.
CONCLUSIONS: Disruptive bleeding in THA was viewed as a composite construct defined by care-altering events rather than numeric blood-loss measures. These findings are exploratory, hypothesis-generating, and identify candidate domains for future multidisciplinary and prospective validation.